

PREFERRED DRUG LIST ADVISORY COMMITTEE MEETING
OCTOBER 30, 2003—CHEYENNE, WYOMING—THE PLAINS HOTEL

MORNING SESSION:

Present:

Scott Johnston, MD—Family Practice
Wright, WY

William Harrison, MD—Internist
Cheyenne Medical Specialists
Cheyenne, WY

James Broomfield, MD
UW Family Practice
Cheyenne, WY

Marion Smith, MD—Family Practice
Torrington Medical Group
Torrington, WY

Chad Panning, PharmD
UW Family Practice
Cheyenne, WY

Bill Marsh—Consumer Representative
State President AARP
Torrington, WY

Bob Schultz, RPh—Pharmacy Director
Blue Cross Blue Shield of Wyoming
Cheyenne, WY

Joyce Dailey
Wyoming Workers' Compensation
Cheyenne, WY

Marian McDonagh, PharmD
Assistant Professor, Division of Medical Informatics and Outcomes
Research

Absent:

Becky Drnas, RPh
KMart Pharmacy
Rock Springs, WY

School of Medicine
Coordinator, Oregon Evidence Based Practice Center

Debra Devereaux, RPh, MBA

Manager Wyoming Drug Utilization Review
Laramie, WY

Dr. Brent Sherard—Deputy Director

Wyoming Department of Health
Cheyenne, WY

Dr. Gary Melinkovich—Staff Physician

Wyoming Department of Health
Cheyenne, WY

Aimee Lewis, PharmD

Wyoming Department of Health
Cheyenne, WY

Travis Fallgren, Wyoming Department of Health Pharmacy Intern
University of Wyoming
Laramie, WY

Susan Malm, Pharmacy Program Coordinator

Wyoming Department of Health
Cheyenne, WY

Several representatives from drug manufacturers

Aimee Lewis, PharmD, opened the meeting and asked members of the Preferred Drug List Advisory Committee (PDLAC) to plan to elect a chair and a vice chair during lunch.

Dr. Lewis also asked the committee to keep cost issues out of all discussions and out of all decisions regarding recommendations for Wyoming's Preferred Drug List. She stressed that the State of Wyoming would choose drugs for the list based on the committee's recommendations in addition to cost considerations. The Wyoming Department of Health would institute the Prior

Authorization criteria for all selected drugs through the Wyoming Drug Utilization Review Board.

At this point, Bill Marsh, AARP stated his concerns regarding safety and appropriateness and Dr. Scott Johnston wanted to know “The cost of switching.”

Dr. Lewis introduced Dr. Marian McDonagh, PharmD, of the Oregon Evidence Based Practice Center. Dr. McDonagh began her tutorial on drug class reviews, namely our first class, PPI’s

Key points must be addressed when reviewing a drug class:

The Oregon EPC must:

- Draft key questions they are trying to answer, i.e., efficacy, safety, population sub groups, cost effectiveness, outcomes, etc.
- Draft inclusion criteria
- Draft exclusion criteria

Dr. McDonagh then gave some suggestions for reviewing the draft reports for each individual class. She noted that these are large reviews and pinpointed a few areas in the text that the committee should look at, namely:

- The section of the report with graphs and plots (44-53 for PPI’s). These give a bird’s eye view as to confidence intervals and points out significant statistical differences. The accompanying text talks at length about differences and gives a quick look as to what is going on in studies within a class.
- Method Section—Details the literature search
- Study Section—A careful description as to how inclusion criteria was applied (what did the Center take from each study—what was consistent from study to study).
- Validity Assessment
 - Internal validity assessment—somewhat subjective because each study reviewed is rated as good/fair/or poor quality. They must have a fatal flaw to be determined poor—randomization, allocation concealment, etc.).
 - External validity assessment
- Appendix B—Assessment of Quality Criteria for controlled studies, reports of complications/adverse effects, economic studies, etc.
- Summary Table—All information is summarized here, question by question; quality of evidence, and conclusions.

Dr. McDonagh then pointed out the example of the Subcommittee Report. This may be used as an example of how a committee took a large amount of information and reached a consensus in their own group.

Next, she explained the preliminary update—a report providing a list of studies published since the original literature searches were conducted that would meet the original inclusion criteria.

Dr. McDonagh also walked the committee through the Final Report section and explained that everything added to the original report has been highlighted. New searches are described and there is a discussion of what was found. New items are highlighted on the summary tables as well. She wanted to be sure that the committee understood that there is always an opportunity to update key questions, outcome measures, etc.

A slide show section is provided and Dr. McDonagh stressed how difficult it is to condense such a large report into 20 slides. An Executive Summary is also included in the review and it is difficult to write as well, but both of these are important documents and should be reviewed by each committee member before the advisory committee meetings convene. There can be situations where updates do make a very large difference in the decision of a committee.

This concluded Dr. McDonagh's presentation and Debra Devereaux, Wyoming Drug Utilization Review Manager explained to the group that all activities related to the Preferred Drug List Advisory Committee will be coordinated through the University of Wyoming School of Pharmacy. All mailings for the committee members will originate at the school. Duties of the chair were outlined: design meeting agendas; work with Debra Devereaux and the Wyoming Department of Health; attend 4 meetings per year in Cheyenne; manage the flow of information etc. The Wyoming Department of Health will give guidance as to the drug classes the committee will review. All recommendations made by the Preferred Drug List Advisory Committee after reviewing evidence will come via the DUR Board to the Wyoming Department of Health.

At this time, all members of the committee introduced themselves and Dr. Marion Smith was nominated as Chair of the PDL Advisory Committee and Dr. Bill Harrison as Vice-Chair. The initial term was designated as 2 years. The committee thought it would provide important continuity until all activities of the committee were stabilized. Deb Devereaux reiterated that the flow of information to committee members would originate from the University of

Wyoming School of Pharmacy. Committee members need not worry that there will be information provided from any other sources. All questions from the press or drug companies should be routed through the Wyoming Department of Health or the University and contact information was provided: e-mail links to the Wyoming Department of Health (<http://wdh.state.wy.us>), the DUR website at (<http://uwacadweb.uwyo.edu/DUR>), and the Preferred Drug List website at (<http://uwacadweb.uwyo.edu/PDL>).

Corrections to contact information was provided by Dr. Scott Johnston, Dr. Broomfield, and Dr. Harrison. The Wyoming Department of Health will update the information and send it out electronically to all committee members.

The time frame for the next meeting was discussed and was left open. The committee is looking at a spring meeting due to weather and the upcoming legislative session. Statins will not be looked at unless the update is complete. The next class to be reviewed by Oregon will be angiotensin receptor blockers. If any of the committee members have questions they would like submitted or included in discussion with the Oregon Center, please submit them by 11/6/2003 for inclusion.

